|1.||Limtrakul, Pornngarm: 2 articles (01/2013 - 12/2011)|
|2.||Ung, Alison T: 1 article (01/2013)|
|3.||Sastraruji, Kwankamol: 1 article (01/2013)|
|4.||Jatisatienr, Araya: 1 article (01/2013)|
|5.||Pintha, Komsak: 1 article (01/2013)|
|6.||Pitchakarn, Pornsiri: 1 article (01/2013)|
|7.||Pyne, Stephen G: 1 article (01/2013)|
|8.||Umsumarng, Sonthaya: 1 article (01/2013)|
|9.||Sastraruji, Thanapat: 1 article (01/2013)|
|10.||Ambudkar, Suresh V: 1 article (12/2011)|
12/01/2011 - "In the present study, we have focused on the effect of stemofoline on the modulation of P-gp function in a multidrug resistant human cervical carcinoma cell line (KB-V1). "
01/01/2013 - "We examined the multidrug resistance reversing property of stemofoline derivatives in drug-resistance human cervical carcinoma (KB-V1) and human leukemic (K562/Adr) cell lines that overexpress P-gp. "
12/01/2011 - "Taken together, the results exhibit that stemofoline possesses an effective MDR modulator, and may be used in combination with conventional chemotherapeutic drugs to reverse MDR in cancer cells."
01/01/2013 - "These results indicate that stemofoline derivatives reversed P-gp-mediated multidrug resistance in vitro, and thus could be developed as effective chemosensitizers to treat multidrug-resistant cancers. "
01/01/2013 - "We found that three out of the twelve stemofoline derivatives including OH-A1, NH-B6 and NH-D6 showed commitment efficiency to increase sensitivity to doxorubicin, vinblastine and paclitaxel in KB-V1 cells and increase sensitivity to doxorubicin, and paclitaxel in K562/Adr cells whereas the effects have not been seen in their parental sensitive cancer cell lines (KB-3-1 and K562). "
|3.||Vinblastine (Vinblastine Sulfate)